Pharmacology of Insulin and Glucagon

1. Introduction/Overview

The endocrine pancreas plays a central role in metabolic homeostasis, primarily through the secretion of two polypeptide hormones with opposing actions: insulin and glucagon. The pharmacology of these agents is foundational to the management of diabetes mellitus, a chronic metabolic disorder characterized by hyperglycemia resulting from defects in insulin secretion, insulin action, or both. Beyond diabetes, these hormones and their analogs are critical in managing various metabolic emergencies and disorders. A thorough understanding of their pharmacodynamics, pharmacokinetics, and clinical applications is essential for rational therapeutic decision-making.

The clinical relevance of insulin and glucagon pharmacology cannot be overstated. Insulin therapy remains a cornerstone for the management of type 1 diabetes mellitus (T1DM) and is frequently required in advanced type 2 diabetes mellitus (T2DM). The development of various insulin formulations and analogs has allowed for more physiological replacement strategies, improving glycemic control while potentially mitigating the risk of hypoglycemia. Glucagon serves as a vital emergency treatment for severe hypoglycemia and has diagnostic applications. Furthermore, the therapeutic landscape is expanding with agents that modulate the glucagon-like peptide-1 (GLP-1) axis, which influences both insulin and glucagon secretion.

Learning Objectives

• Describe the physiological roles, mechanisms of action, and receptor signaling pathways of insulin and glucagon.
• Compare and contrast the pharmacokinetic properties of various insulin formulations (rapid-acting, short-acting, intermediate-acting, long-acting, and ultra-long-acting) and glucagon.
• Identify the approved therapeutic indications, clinical applications, and dosing strategies for insulin and glucagon in different patient populations.
• Analyze the spectrum of adverse effects, contraindications, and major drug interactions associated with insulin and glucagon therapy.
• Apply knowledge of special considerations, including use in pregnancy, pediatrics, geriatrics, and renal or hepatic impairment, to optimize patient-specific therapeutic plans.

2. Classification

Insulin and glucagon preparations are classified based on their source, duration of action, and molecular structure.

Insulin Classifications

By Source and Production:

• Animal-source Insulins: Historically derived from bovine or porcine pancreata. Bovine insulin differs from human insulin by three amino acids, while porcine insulin differs by one. Their use has declined significantly due to the advent of human insulin and analogs, which are associated with lower immunogenicity.
• Human Insulin: Produced via recombinant DNA technology using Escherichia coli or Saccharomyces cerevisiae. These are identical in amino acid sequence to endogenous human insulin (e.g., regular insulin, NPH insulin).
• Insulin Analogs: Genetically engineered modifications of the human insulin molecule designed to alter pharmacokinetic profiles. These are the mainstay of modern therapy.

By Duration of Action:

• Rapid-acting Analogs: Insulin lispro, aspart, and glulisine. Characterized by a fast onset (5-15 minutes) and short duration (3-5 hours) due to modifications that prevent hexamer formation, allowing rapid monomer absorption.
• Short-acting (Regular): Human regular insulin. Onset is 30-60 minutes, peak at 2-4 hours, duration 5-8 hours. Must be administered 30 minutes before meals.
• Intermediate-acting: Neutral Protamine Hagedorn (NPH) insulin. Protamine delays absorption, providing an onset of 1-2 hours, peak of 4-12 hours, and duration of 18-24 hours. It has a pronounced peak, increasing hypoglycemia risk.
• Long-acting Analogs: Insulin glargine and detemir. Glargine is precipitated at subcutaneous pH, forming a slow-release depot. Detemir is acylated, promoting albumin binding. Both provide relatively peakless basal insulin coverage for approximately 24 hours (detemir may require twice-daily dosing in some).
• Ultra-long-acting Analogs: Insulin degludec. Forms multi-hexamers upon injection that dissociate very slowly, resulting in an ultra-long, stable action profile exceeding 42 hours with minimal peak.
• Premixed Formulations: Fixed-ratio combinations of rapid- or short-acting insulin with intermediate-acting insulin (e.g., 70/30 NPH/regular, 75/25 lispro protamine/lispro).

Glucagon Classifications

• Native Glucagon: A 29-amino acid polypeptide hormone identical to endogenous human glucagon. It is derived from recombinant DNA technology or extracted from animal pancreata.
• Glucagon Analogs: Dasiglucagon is a stable, liquid-stable glucagon analog approved for severe hypoglycemia.
• Glucagon Receptor Agonists: While not used therapeutically for glycemic rescue, this classification is relevant for understanding drug actions on the glucagon receptor.

3. Mechanism of Action

Insulin Pharmacodynamics

Insulin exerts its effects by binding to the insulin receptor, a transmembrane tyrosine kinase receptor composed of two extracellular α-subunits and two transmembrane β-subunits. Binding induces a conformational change, activating the receptor’s intrinsic tyrosine kinase activity. This leads to autophosphorylation of the β-subunits and subsequent phosphorylation of intracellular substrate proteins, primarily the insulin receptor substrates (IRS-1 to IRS-4).

The phosphorylated IRS proteins activate two principal signaling pathways:

1. The PI3-Kinase/Akt Pathway: This is the primary metabolic pathway. Activation of phosphatidylinositol 3-kinase (PI3K) and protein kinase B (Akt/PKB) stimulates the translocation of glucose transporter type 4 (GLUT4) vesicles to the cell membrane in muscle and adipose tissue, facilitating glucose uptake. This pathway also promotes glycogen synthesis, protein synthesis, and lipogenesis while inhibiting gluconeogenesis, glycogenolysis, lipolysis, and proteolysis.
2. The MAP-Kinase Pathway: Activated via Ras/Raf/MEK/ERK, this pathway mediates insulin’s mitogenic and growth-promoting effects, influencing cell proliferation and differentiation.

The net physiological effects are anabolic: reduction of blood glucose (via increased peripheral uptake and decreased hepatic output), promotion of energy storage (glycogen, triglycerides), and stimulation of protein synthesis.

Glucagon Pharmacodynamics

Glucagon acts as a counter-regulatory hormone to insulin. It binds to a specific G protein-coupled receptor (GPCR) on hepatocytes. Receptor activation stimulates adenylate cyclase via the G_s protein, increasing intracellular cyclic adenosine monophosphate (cAMP). Elevated cAMP activates protein kinase A (PKA), which in turn phosphorylates and activates key enzymes.

The primary molecular and cellular consequences are:

• Glycogenolysis: PKA phosphorylates and activates phosphorylase kinase, which then activates glycogen phosphorylase, breaking down glycogen to glucose-1-phosphate, and subsequently glucose-6-phosphate, for release as free glucose into the bloodstream.
• Gluconeogenesis: PKA promotes the transcription of phosphoenolpyruvate carboxykinase (PEPCK) and glucose-6-phosphatase, key enzymes in gluconeogenesis, while inhibiting glycolysis and pyruvate kinase.
• Lipolysis and Ketogenesis: In adipose tissue, glucagon stimulates hormone-sensitive lipase, increasing free fatty acid release. In the liver, these fatty acids are oxidized, leading to ketone body (acetoacetate, β-hydroxybutyrate) production.

The net effect is catabolic: a rapid increase in blood glucose, mobilization of stored energy, and, under prolonged action, ketosis.

4. Pharmacokinetics

Insulin Pharmacokinetics

Absorption: All therapeutic insulins are administered via subcutaneous injection, with absorption being the rate-limiting step. Absorption kinetics are influenced by the formulation, injection site (abdomen fastest, arm intermediate, thigh and buttock slowest), depth of injection, local blood flow, temperature, and physical activity. Intravenous administration is used in emergencies (e.g., diabetic ketoacidosis) and provides immediate effect with a very short half-life (≈5 minutes). Inhaled insulin is available as a rapid-acting formulation.

Distribution: Insulin distributes into a volume roughly equivalent to the extracellular fluid. It does not cross the placenta significantly. Insulin analogs like detemir are highly bound to albumin in the circulation, which contributes to their prolonged action.

Metabolism and Excretion: Insulin is metabolized primarily in the liver (≈60%) and kidneys (≈30-40%) via insulin-degrading enzyme (IDE) and other proteases. Renal clearance becomes increasingly important in renal impairment. The metabolites are inactive and excreted. The terminal half-life after intravenous administration is short, but the effective half-life after subcutaneous administration is determined by the rate of absorption from the depot.

Pharmacokinetic Parameters of Key Insulin Formulations:

• Rapid-acting Analogs (Lispro, Aspart, Glulisine): Onset: 5-15 min; Peak: 30-90 min; Duration: 3-5 hours. t_max ≈ 1 hour.
• Short-acting (Regular): Onset: 30-60 min; Peak: 2-4 hours; Duration: 5-8 hours. t_max ≈ 2-3 hours.
• Intermediate-acting (NPH): Onset: 1-2 hours; Peak: 4-12 hours; Duration: 18-24 hours. Pronounced peak.
• Long-acting Analogs (Glargine U100, Detemir): Onset: 1-2 hours; Peak: relatively peakless; Duration: 18-24 hours (detemir may be shorter). t_1/2 ≈ 12 hours.
• Ultra-long-acting Analogs (Degludec, Glargine U300): Onset: 1-2 hours; No pronounced peak; Duration: >42 hours (degludec) or >24 hours (glargine U300). Terminal t_1/2 of degludec is ≈25 hours.

Glucagon Pharmacokinetics

Absorption: For emergency use, glucagon is administered via intramuscular, subcutaneous, or intravenous injection. Intranasal and stable subcutaneous formulations (dasiglucagon) are also available. After intramuscular/subcutaneous injection for hypoglycemia, the onset of action is typically within 10-15 minutes.

Distribution: Glucagon distributes widely but acts primarily on hepatic receptors. It does not cross the blood-brain barrier effectively.

Metabolism and Excretion: Glucagon is rapidly degraded in the liver, kidneys, and plasma. Its plasma half-life is approximately 3-6 minutes, but its hyperglycemic effect lasts for 60-90 minutes due to the persistence of its second messenger (cAMP) and the time required for hepatic glucose production and release.

5. Therapeutic Uses/Clinical Applications

Insulin

Approved Indications:

• Type 1 Diabetes Mellitus: Lifelong, absolute insulin deficiency necessitates basal-bolus replacement therapy, typically involving a long-acting analog for basal needs and a rapid-acting analog for prandial coverage.
• Type 2 Diabetes Mellitus: Initiated when glycemic control is not achieved with non-insulin agents (e.g., metformin, GLP-1 receptor agonists). May start with basal insulin, progressing to basal-bolus or premixed regimens as β-cell function declines.
• Gestational Diabetes Mellitus: Used when medical nutrition therapy fails to achieve glycemic targets. Insulin is preferred as it does not cross the placenta.
• Diabetic Ketoacidosis (DKA) and Hyperosmolar Hyperglycemic State (HHS): Regular insulin is administered via continuous intravenous infusion for precise titration and rapid correction.
• Hyperkalemia: The administration of insulin (with glucose to prevent hypoglycemia) stimulates cellular uptake of potassium via Na⁺/K⁺-ATPase activation, providing a temporizing measure for severe hyperkalemia.
• Perioperative Management and Critical Illness: Insulin infusion is standard for maintaining glycemic control in critically ill patients and during major surgeries.

Glucagon

Approved Indications:

• Severe Hypoglycemia: The primary indication is the treatment of severe hypoglycemia (altered mental status, unconsciousness, inability to ingest oral carbohydrates) in individuals with diabetes. It is a life-saving intervention.
• Diagnostic Aid: Used in radiology to inhibit gastrointestinal motility (e.g., for MRI of the bowel) and in stimulating insulin secretion during diagnostic testing for insulinoma (glucagon stimulation test).
• β-blocker or Calcium Channel Blocker Overdose: Glucagon’s positive inotropic and chronotropic effects, mediated via increased myocardial cAMP, can be useful in overdoses with these cardiotoxic agents, though evidence is primarily from case reports.

Off-label Uses: Investigationally used for hypotension secondary to anaphylaxis refractory to epinephrine, due to its inotropic effects.

6. Adverse Effects

Insulin Adverse Effects

Common Side Effects:

• Hypoglycemia: The most frequent and serious acute adverse effect. Symptoms range from autonomic (tremor, sweating, palpitations) to neuroglycopenic (confusion, drowsiness, seizure, coma). Risk is increased with tighter glycemic control, erratic meals, exercise, renal impairment, and certain insulin types (e.g., NPH).
• Weight Gain: Anabolic effects of insulin promote lipogenesis and inhibit lipolysis, often leading to weight gain, which can exacerbate insulin resistance.
• Injection Site Reactions: Lipohypertrophy (fatty tissue growth), lipoatrophy (fatty tissue loss, now rare with human/analog insulins), redness, itching, or pain.
• Hypokalemia: Insulin stimulates cellular potassium uptake, which can be significant during treatment of DKA or with high-dose insulin therapy.

Serious/Rare Adverse Reactions:

• Severe Hypoglycemia: Can lead to seizures, coma, permanent neurological damage, arrhythmias, and death.
• Allergic Reactions: Localized IgE-mediated reactions are uncommon with modern insulins. Systemic anaphylaxis is extremely rare.
• Sodium and Water Retention: May occur with initiation of intensive insulin therapy, potentially exacerbating heart failure (insulin edema).
• Mitogenic Potential: Theoretical concern due to activation of the MAP-kinase pathway, but clinical evidence linking insulin analogs to increased cancer risk remains inconclusive and controversial.

Black Box Warnings: None for insulin itself, but all insulin products carry a general warning regarding the risk of hypoglycemia.

Glucagon Adverse Effects

Common Side Effects:

• Nausea and Vomiting: Very common, occurring in a significant proportion of patients, likely due to central and gastrointestinal effects.
• Hyperglycemia: The intended therapeutic effect in hypoglycemia; however, rebound hyperglycemia can occur.
• Tachycardia and Hypertension: Due to its positive inotropic and chronotropic effects.

Serious/Rare Adverse Reactions:

• Hypersensitivity Reactions: Anaphylaxis has been reported, particularly with older animal-derived preparations.
• Hyperglycemia in Patients with Insulinoma: Can provoke a paradoxical hypoglycemic episode following the initial hyperglycemia due to excessive insulin release from the tumor.

Black Box Warnings: None for glucagon.

7. Drug Interactions

Insulin Drug Interactions

Drugs that May Increase Hypoglycemic Risk (Additive/Synergistic Effects):

• Other Antidiabetic Agents: Sulfonylureas, meglitinides, GLP-1 receptor agonists, SGLT2 inhibitors, metformin.
• β-adrenergic Blockers (non-selective): Mask tachycardia, a key warning sign of hypoglycemia, and may impair gluconeogenesis.
• Angiotensin-Converting Enzyme (ACE) Inhibitors: May improve insulin sensitivity.
• Fluoroquinolones (e.g., gatifloxacin, discontinued), Pentamidine: Can cause hypoglycemia via pancreatic islet cell toxicity.
• Salicylates (high dose), Disopyramide: Have intrinsic hypoglycemic effects.
• Alcohol: Inhibits gluconeogenesis, increasing the risk of delayed hypoglycemia, especially in a fasting state.

Drugs that May Increase Blood Glucose (Antagonistic Effects):

• Corticosteroids: Potent inducers of insulin resistance and gluconeogenesis.
• Thiazide Diuretics: May cause hyperglycemia via hypokalemia-induced impairment of insulin secretion.
• Sympathomimetics (e.g., albuterol, epinephrine): Stimulate glycogenolysis and gluconeogenesis.
• Atypical Antipsychotics (e.g., olanzapine, clozapine): Cause weight gain and insulin resistance.
• Protease Inhibitors, Niacin: Can induce insulin resistance.
• Thyroid Hormone Replacement: Increases metabolic rate and may raise insulin requirements.

Contraindications: Insulin therapy is contraindicated during episodes of hypoglycemia. There are no absolute contraindications to insulin in the setting of hyperglycemia requiring treatment, though caution is advised in settings where hypoglycemia risk is extreme and cannot be mitigated.

Glucagon Drug Interactions

Major Drug-Drug Interactions:

• β-adrenergic Blockers: The cardiac effects of glucagon may be blunted by non-selective β-blockers, potentially reducing its efficacy in treating overdose of these agents.
• Anticholinergics: Concomitant use with glucagon for diagnostic purposes may have additive inhibitory effects on gastrointestinal motility.
• Warfarin: Case reports suggest glucagon may potentiate the anticoagulant effect, possibly by reducing vitamin K-dependent clotting factor synthesis; monitoring of INR is advised.

Contraindications: Glucagon is contraindicated in patients with pheochromocytoma (risk of catecholamine release and hypertensive crisis) and insulinoma (risk of rebound hypoglycemia). It is also contraindicated in patients with known hypersensitivity to glucagon or any component of the formulation.

8. Special Considerations

Pregnancy and Lactation

Insulin: Insulin is the drug of choice for glycemic control in pregnancy (pregestational and gestational diabetes) as it does not cross the placenta. Requirements often increase in the second and third trimesters due to placental hormone-induced insulin resistance and then drop precipitously after delivery. Human insulin and insulin analogs (especially aspart and detemir, with more pregnancy data) are considered safe. Insulin is compatible with breastfeeding; doses may need adjustment postpartum as lactation increases glucose utilization.

Glucagon: Glucagon is classified as Pregnancy Category B. No adequate, well-controlled studies exist in pregnant women. It should be used during pregnancy only if clearly needed for severe hypoglycemia. It is not known whether glucagon is excreted in human milk; caution is advised if administered to a nursing woman.

Pediatric and Geriatric Considerations

Pediatrics (Insulin): Insulin is the mainstay for T1DM in children. Dosing is highly individualized and based on weight, age, pubertal status, and carbohydrate intake. Rapid-acting analogs are preferred for meal coverage due to flexible timing. Careful education of caregivers on hypoglycemia recognition and management is critical. Continuous subcutaneous insulin infusion (insulin pumps) are commonly used.

Geriatrics (Insulin): Older adults are at increased risk for hypoglycemia due to blunted counter-regulatory responses, polypharmacy, renal impairment, and cognitive dysfunction. Simpler regimens (e.g., once-daily basal insulin) may be preferred over complex basal-bolus therapy to reduce hypoglycemia risk. Glycemic targets are often less stringent.

Glucagon: In both populations, the indications remain the same. For children, dose is weight-based (0.5 mg for <25 kg, 1 mg for ≥25 kg). For elderly patients, standard doses are used, but caregivers must be trained in administration due to the potential for cognitive or physical limitations.

Renal and Hepatic Impairment

Renal Impairment:
Insulin: Renal clearance of insulin is reduced, increasing its half-life and effect duration. The risk of hypoglycemia is significantly elevated. Insulin requirements often decrease as renal function declines. Careful dose reduction and frequent glucose monitoring are mandatory. All insulin types can be used with caution.
Glucagon: Pharmacokinetics may be altered, but no specific dose adjustment guidelines exist. Efficacy in raising blood glucose relies on hepatic glycogen stores, which may be depleted in advanced renal disease associated with malnutrition.

Hepatic Impairment:
Insulin: Hepatic insulin metabolism is impaired, reducing clearance. Furthermore, hepatic insulin resistance and impaired gluconeogenesis are often present in cirrhosis. This creates a complex scenario: basal insulin requirements may be lower due to reduced clearance, but prandial requirements may be higher due to insulin resistance. Hypoglycemia risk is high due to impaired gluconeogenesis. Extreme caution and frequent monitoring are required.
Glucagon: The primary site of glucagon action and metabolism is the liver. In severe hepatic impairment (e.g., cirrhosis, hepatitis), the glycogenolytic response to glucagon may be markedly blunted or absent due to depleted glycogen stores. Its efficacy for treating hypoglycemia is therefore unreliable in this population.

9. Summary/Key Points

• Insulin and glucagon are pivotal counter-regulatory hormones governing glucose homeostasis. Insulin promotes anabolic processes and lowers blood glucose, while glucagon stimulates catabolic processes to raise blood glucose.
• Modern insulin therapy is dominated by recombinant human insulin and, more commonly, engineered analogs classified by their duration of action: rapid-, short-, intermediate-, long-, and ultra-long-acting. Their pharmacokinetic profiles guide their use in basal or prandial replacement strategies.
• Insulin acts via the tyrosine kinase insulin receptor, activating PI3K/Akt (metabolic) and MAPK (mitogenic) pathways. Glucagon acts via a GPCR, increasing cAMP and activating PKA to stimulate glycogenolysis and gluconeogenesis.
• The primary indication for insulin is the treatment of diabetes mellitus (types 1 and 2, gestational). Glucagon’s primary indication is the emergency treatment of severe hypoglycemia.
• Hypoglycemia is the most common and dangerous adverse effect of insulin therapy. Nausea and vomiting are common with glucagon administration.
• Numerous drugs interact with insulin, either potentiating its hypoglycemic effect (e.g., sulfonylureas, β-blockers, alcohol) or antagonizing it (e.g., corticosteroids, thiazides).
• Special populations require careful consideration: insulin needs change dynamically during pregnancy; elderly and renally impaired patients are at high risk for hypoglycemia; and glucagon may be ineffective in severe hepatic impairment.

Clinical Pearls

• When initiating insulin in type 2 diabetes, start with a low dose of a long-acting analog (e.g., 0.1-0.2 units/kg) at bedtime and titrate based on fasting glucose, not postprandial values.
• “Stacking” insulin doses—administering a rapid-acting dose too soon after a previous dose—is a common cause of unexpected hypoglycemia.
• The efficacy of glucagon for severe hypoglycemia is entirely dependent on adequate hepatic glycogen stores. It will be ineffective in starved patients or those with advanced liver disease.
• In a patient with recurrent, unexplained hypoglycemia, consider factitious hypoglycemia from surreptitious insulin or sulfonylurea use. A diagnostic triad of hypoglycemia with high insulin, low C-peptide, and low proinsulin suggests exogenous insulin administration.
• Always confirm the concentration of insulin (U-100 vs. U-500) before administration or prescribing, as dosing errors can be fatal.

References

1. Whalen K, Finkel R, Panavelil TA. Lippincott Illustrated Reviews: Pharmacology. 7th ed. Philadelphia: Wolters Kluwer; 2019.
2. Rang HP, Ritter JM, Flower RJ, Henderson G. Rang & Dale's Pharmacology. 9th ed. Edinburgh: Elsevier; 2020.
3. Brunton LL, Hilal-Dandan R, Knollmann BC. Goodman & Gilman's The Pharmacological Basis of Therapeutics. 14th ed. New York: McGraw-Hill Education; 2023.
4. Katzung BG, Vanderah TW. Basic & Clinical Pharmacology. 15th ed. New York: McGraw-Hill Education; 2021.
5. Golan DE, Armstrong EJ, Armstrong AW. Principles of Pharmacology: The Pathophysiologic Basis of Drug Therapy. 4th ed. Philadelphia: Wolters Kluwer; 2017.
6. Trevor AJ, Katzung BG, Kruidering-Hall M. Katzung & Trevor's Pharmacology: Examination & Board Review. 13th ed. New York: McGraw-Hill Education; 2022.
7. Whalen K, Finkel R, Panavelil TA. Lippincott Illustrated Reviews: Pharmacology. 7th ed. Philadelphia: Wolters Kluwer; 2019.
8. Rang HP, Ritter JM, Flower RJ, Henderson G. Rang & Dale's Pharmacology. 9th ed. Edinburgh: Elsevier; 2020.